Literature DB >> 8126205

Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens.

S S Altaie1, P Meyer, D Dryja.   

Abstract

Clostridium difficile is the cause of most cases of pseudomembranous colitis, the most severe form of antibiotic-associated diarrhea. Rapid diagnosis guides both the treatment and the control of nosocomial spread of infection. Two enzyme immunoassay (EIA) kits developed for the rapid detection of C. difficile toxin A in fecal specimens, Premier (Meridian Diagnostics, Cincinnati, Ohio) and Tox-A test (TechLab, Virginia Polytechnic Institute Research Park, Blacksburg), were evaluated by using 410 fecal specimens. Seventy-six specimens were positive for C. difficile toxin B by the cytotoxin assay (prevalence rate, 19%). The Meridian EIA was positive for 71 of the 76 samples, yielding a sensitivity of 93%. The TechLab EIA detected 75 of the 76 positive samples, yielding a sensitivity of 99%. The Meridian and TechLab EIAs had specificities of 100 and 93%, respectively. These data indicate that both EIAs are suitable alternatives to the cytotoxin assay in routine diagnostic laboratories. However, confirmation of TechLab EIA-positive test results by the cytotoxin assay remains necessary.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8126205      PMCID: PMC262968          DOI: 10.1128/jcm.32.1.51-53.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Effect of the cytotoxin of Clostridium difficile on cultured hepatoma cells.

Authors:  B Rihn; G Beck; H Monteil; F Lecerf; R Girardot
Journal:  Biol Cell       Date:  1985       Impact factor: 4.458

2.  Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa.

Authors:  C Pothoulakis; G Triadafilopoulos; M Clark; C Franzblau; J T LaMont
Journal:  Gastroenterology       Date:  1986-11       Impact factor: 22.682

3.  Evaluation of a commercial kit for the routine detection of Clostridium difficile cytotoxin by tissue culture.

Authors:  T C Wu; S M Gersch
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

4.  Intoxication of cultured human lung fibroblasts with Clostridium difficile toxin.

Authors:  I Florin; M Thelestam
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

Review 5.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

6.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

7.  Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc.

Authors:  H C Krivan; G F Clark; D F Smith; T D Wilkins
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

8.  Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; N Moon; T W Chang; N Taylor; A B Onderdonk
Journal:  Gastroenterology       Date:  1978-11       Impact factor: 22.682

9.  Clostridium difficile and the aetiology of pseudomembranous colitis.

Authors:  H E Larson; A B Price; P Honour; S P Borriello
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

10.  Effects of Clostridium difficile toxins given intragastrically to animals.

Authors:  D M Lyerly; K E Saum; D K MacDonald; T D Wilkins
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

  10 in total
  2 in total

1.  Tox-A Test for Clostridium difficile.

Authors:  T D Wilkins; D M Lyerly
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

2.  Is Fecal Leukocyte Test a good predictor of Clostridium difficile associated diarrhea?

Authors:  Savio Reddymasu; Ankur Sheth; Daniel E Banks
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-04-19       Impact factor: 3.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.